SLN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 114027 min ago

@ $21.84

Wydano: 14 vas. 2024 @ 22:27

Zwrot: 0.69%

Poprzedni sygnał: vas. 9 - 20:56

Poprzedni sygnał: Sprzedaż

Zwrot: -3.36 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	438 450
Średni wolumen	231 587
Kapitalizacja rynkowa	1.03B
EPS	$0 ( 2024-03-13 )
Następna data zysków	( $-0.230 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.06
ATR14	$0.0320 (0.15%)

Wolumen Korelacja

Długi: -0.44 (neutral)

Krótki: 0.26 (neutral)

Signal:(55.653) Neutral

Silence Therapeutics plc Korelacja

10 Najbardziej pozytywne korelacje
ICHR	0.936
TNYA	0.928
BNIXU	0.924
SRTS	0.919
MGNX	0.912
YMAB	0.908
AVIR	0.906
ISEM	0.905
KYMR	0.904
MRUS	0.904

10 Najbardziej negatywne korelacje
VALN	-0.931
BFRI	-0.899
BOWXU	-0.897
VNET	-0.89
CRCT	-0.888
VRM	-0.886
RTPY	-0.886
GRNA	-0.883
KBNT	-0.881
LHDX	-0.88

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Silence Therapeutics plc Korelacja - Waluta/Towar

-0.15
( neutral )

-0.22
( neutral )

0.00
( neutral )

0.68
( moderate )

-0.23
( neutral )

0.54
( weak )

Silence Therapeutics plc Finanse

Annual	2023
Przychody:	$25.38M
Zysk brutto:	$15.06M (59.34 %)
EPS:	$-1.170

FY	2023
Przychody:	$25.38M
Zysk brutto:	$15.06M (59.34 %)
EPS:	$-1.170

FY	2022
Przychody:	$17.50M
Zysk brutto:	$6.62M (37.83 %)
EPS:	$-1.260

FY	2021
Przychody:	$12.42M
Zysk brutto:	$4.96M (39.94 %)
EPS:	$-1.329

Financial Reports:

No articles found.

Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.